Hepatic AL Amyloidosis without Significant Light Chain Elevation in a Patient Treated with CyBorD Plus Daratumumab

Brad Rybinski; Mehmet Kocoglu

doi:10.12659/AJCR.933241

23 August 2021: Articles

Hepatic AL Amyloidosis without Significant Light Chain Elevation in a Patient Treated with CyBorD Plus Daratumumab

Unusual clinical course, Rare disease

Brad Rybinski ^A* , Mehmet Kocoglu ^A

DOI: 10.12659/AJCR.933241

Am J Case Rep 2021; 22:e933241

Authors information Article notes Copyright and License information

Background Case Report Discussion Conclusions References:

View HTML version

Figure 2. Alkaline phosphatase down-trended with initiation of CyBorD (cyclophosphamide-bortezomibdexamethasone) and then decreased further after daratumumab was added, reflecting organ response. Alkaline phosphatase remained stable after autologous stem cell transplant.

Back to the Article

Hepatic AL Amyloidosis without Significant Light Chain Elevation in a Patient Treated with CyBorD Plus Daratumumab

Your Privacy